Bico–Sartorius: investment, 202404– acquisition 100% of MatTek Corp + Visikol Inc on cash/debt-free basis for $80m by Sartorius Lab Holding GmbH |
2025-04-04 |
GQ Bio Therapeutics–Pacira: investment, 202502 acquisition remaining 81% in GQ Bio for $32m by Pacira |
2025-02-27 |
Phaeosynt–Fonde Ventures: investment, 202502 seed financing round totalling €1.7m incl new investor Fonde Ventures |
2025-02-12 |
Phaeosynt–Lower Saxony (govt): investment, 202502 seed financing round totalling €1.7m incl new investor NBank Capital Beteiligungsgesellschaft mbH |
2025-02-12 |
Phaeosynt–OTHER: investment, 202502 seed financing round totalling €1.7m incl existing investors |
2025-02-12 |
Phaeosynt–PERSON: investment, 202502 seed financing round totalling €1.7m incl new investor Thomas Tönnesmann |
2025-02-12 |
Phaeosynt–PERSON: investment, 202502 seed financing round totalling €1.7m incl new investor Ulrich Gehrke |
2025-02-12 |
Phaeosynt–PSD Bank: investment, 202502 seed financing round totalling €1.7m incl new investor PSD Braunscheig Verwaltungs-GmbH |
2025-02-12 |
Phaeosynt–Renditei: investment, 202502 seed financing round totalling €1.7m incl new investor Renditei UG |
2025-02-12 |
Phaeosynt–SEVERAL: investment, 202502 seed financing round €1.7m from existing + new investors |
2025-02-12 |
Phaeosynt–TrueNorth Ventures: investment, 202502 seed financing round totalling €1.7m incl new investor TrueNorth Ventures UG |
2025-02-12 |
IBA Lifesciences–Cube Biotech: investment, 202501 acquisition of IBA Lifesciences by Cube Biotech backed by majority owner Archimed |
2025-01-13 |
Evotec–Halozyme: investment, 202411 acquisition €2b unsolicited + non-binding cash offer at €11/share refused + withdrawn NOT REALISED |
2024-11-14 |
Centogene–Charme Capital Partners: investment, 202411–202503 acquisition €8.7m of sole operating subsidiary Centogene GmbH by Charme Capital |
2024-11-13 |
Yumab–Molcure: AI-based drug discovery, 202410– collab expansion to incl zero-shot AI Ab discovery technology to discover Abs for undrugged targets |
2024-10-08 |
Dynamic Biosensors–Bruker: investment, 202410 acquisition €na of Dynamic Biosensors GmbH + integration in Bruker Biosensors business |
2024-10-02 |
Novo Group–Evotec: cell therapy manufacturing, 202409– collab technology development €na RnD funding + upfront + milestone payments plus royalties |
2024-09-26 |
Lucid Genomics–BIF Partners: investment, 202408 pre-seed financing round totalling €1.3m incl co-investor BIF Partners |
2024-09-02 |
Allogenetics–Carma Fund: investment, 202408 first financing round totalling €3.4m incl co-lead investor Carma Fund |
2024-08-29 |
Allogenetics–Lower Saxony (govt): investment, 202408 first financing round totalling €3.4m incl co-lead investor NBank Capital |
2024-08-29 |
Allogenetics–OTHER: investment, 202408 first financing round totalling €3.4m incl several business angels |
2024-08-29 |
Allogenetics–SEVERAL: investment, 202408 first financing round €3.4m led by NBank Capital + Carma Fund |
2024-08-29 |
mzio–Bremen (govt): grant, 202408 grant funding €150k from BAB co-funded by EU |
2024-08-21 |
Lignopure–Lower Saxony (govt): investment, 202407 equity financing round totalling €2.4m incl lead investor NBank Capital |
2024-07-17 |
Lignopure–NiedersachsenMetall: investment, 202407 equity financing round totalling €2.4m incl co-investor Niedersachsen Beteiligungs GmbH & Co KG |
2024-07-17 |
Lignopure–OTHER: investment, 202407 equity financing round totalling €2.4m incl existing investors |
2024-07-17 |
Lignopure–OTHER: investment, 202407 equity financing round totalling €2.4m incl a Family Office as co-investor |
2024-07-17 |
Lignopure–RaakWark Kaptaal: investment, 202407 equity financing round totalling €2.4m incl co-investor RaakWark Kaptaal |
2024-07-17 |
Lignopure–SEVERAL: investment, 202407 equity financing round €2.4m led by NBank Capital |
2024-07-17 |
Carelane–High-Tech Gründerfonds: investment, 202406 pre-seed financing round totalling €800k incl lead investor HTGF |
2024-06-20 |
Carelane–SEVERAL: investment, 202406 pre-seed financing round €800k led by HTGF |
2024-06-20 |
Mondi–Traceless Materials: biomaterials, 202406– collab strategic partnership using traceless material for paper coating solutions |
2024-06-18 |
PINK gegen Brustkrebs–Sidekick Health: investment, 202406 acquisition of PINK! by Sidekick Health |
2024-06-18 |
ITM–Carbyne Equity Partners: investment, 202406 financing round totalling €188m incl exisitng + co-investor Carbyne Equity Partners |
2024-06-06 |
Evotec–Qiagen: bioinformatics, 202406– collab integration of OmicSoft Land Databases with PanHunter platform for partners + clients |
2024-06-03 |
Sartorius–Nvidia: AI-based drug discovery + manufacturing, 202405– collab expansion incl adaption of Nvidia Clara Suite + DGX platform |
2024-05-16 |
Sartorius–Sanofi: biopharmaceutical production technology, 202405– collab + license developm of ICB platform to be excl commercialised by Sartorius ww |
2024-05-13 |
Topas Therapeutics–Trophic Communications: public relations, 202405 service existent by Trophic |
2024-05-01 |
Bayer–Evotec: drug discovery services, 202404– update to strategic collab €na with new focus on precision cardiology usinsg iPSCs |
2024-04-30 |
Cultimate Foods–Life Science Valley: investment, 202404 seed financing round totalling €2.3m incl co-investor LSV Wachstumsfonds |
2024-04-23 |
Innocent Meat–Mecklenburg-Vorpommern (govt): investment, 202403 financing round totalling €3m incl €500k from existing investor VC Fonds MV |
2024-03-26 |
Innocent Meat–OTHER: investment, 202403 financing round totalling €3m incl €2.5m from a new private investor |
2024-03-26 |
Innocent Meat–SEVERAL: investment, 202403 financing round €3m with Venture Capital Fonds MV + new private investor |
2024-03-26 |
Protembis–SEVERAL: investment, –202403 financing round Series B €30m completed in two separate capital increases |
2024-03-26 |
Cardior Pharmaceuticals–Novo Group: investment, 202403– acquisition for up to €1.025b incl upfront payment + milestones ANNOUNCED |
2024-03-25 |
Tubulis–Evotec: investment, 202403 financing round Series B2 totalling €128m incl existing + co-investor Evotec |
2024-03-14 |
HiDocTechnologies–Mahana Therapeutics: investment, 202403 acquisition €na of Cara Care by Mahana Therapeutics |
2024-03-12 |
Cellbox Solutions–EU (govt): investment, 2024– equity investment up to €10m from EIC Accelerator |
2024-01-01 |
Aidhere–Sidekick Health: investment, 202310 acquisition of Aidhere out of bankrupcty by Sidekick Health |
2023-10-10 |
Traceless Materials–b.value: investment, 202309 financing round Series A totalling €36.6m incl existing + co-investor b.value |
2023-09-25 |
Traceless Materials–GLS Bank: investment, 202309 financing round Series A totalling €36.6m incl new + co-investor GLS Bank Hamburg |
2023-09-25 |
Traceless Materials–High-Tech Gründerfonds: investment, 202309 financing round Series A totalling €36.6m incl existing + co-investor HTGF |
2023-09-25 |
Traceless Materials–Planet A: investment, 202309 financing round Series A totalling €36.6m incl existing + co-investor Planet A Ventures |
2023-09-25 |
Traceless Materials–SEVERAL: investment, 202309 financing round Series A €36.6m led by UB FIGG plus other new + all existing investors |
2023-09-25 |
Traceless Materials–Sparkassen (DE): investment, 202309 financing round Series A totalling €36.6m incl new + co-investor HaSpa |
2023-09-25 |
Traceless Materials–SWEN Capital Partners: investment, 202309 financing round Series A totalling €36.6m incl new + co-lead investor Blue Ocean fund |
2023-09-25 |
Traceless Materials–United Bankers: investment, 202309 financing round Series A totalling €36.6m incl new + lead investor UB FIGG |
2023-09-25 |
CrystalsFirst–Helmholtz: drug discovery technology, 202309–202410 collab developm in joint project LigandML with DESY with funding from IFB Hamburg |
2023-09-01 |
Takara Shuzo–Eppendorf: lab automation equipment, 202308– collab strategic co-marketing agreem automating Takara Bio chemistries on epMotion platforms |
2023-08-25 |
Cellbox Solutions–EU (govt): grant, 202308–202507 EIC Accelerator grant €2.5m |
2023-08-01 |
Cellbox Solutions–Akampion: public relations, 202307 service existent by Akampion |
2023-07-05 |
ITM–Carbyne Equity Partners: investment, 202306 financing round totalling €255m incl new + co-investor Carbyne Equity Partners |
2023-06-05 |
Sartorius–Waters: biopharma production technology, 202306– collab expansion integration of PATROL UPLC PAS with Resolute BioSMB platform |
2023-06-05 |
Traceless Materials–Germany (govt): grant, 202305– BMUV funding €5.1m for construction of demonstration plant |
2023-05-19 |
BMS–Evotec: drug discovery services, 202303–203102 strategic RnD collab expansion 8 years $50m upfront + total potential $4b neurodegenerative drugs |
2023-03-28 |
Cellbox Solutions–SEVERAL: investment, 202303 financing round Series A1 €6.5m led by CK Ventures |
2023-03-07 |
Calibre Scientific–Eppendorf: micromanipulation products, 202303 acquisition of micromanipulation product portfolio of Eppendorf by Calibre Scientific |
2023-03-06 |
Akttya Therapeutics–CrystalsFirst: drug discovery services, 202302– supply service €na using SmartSoak technology on novel protein targets of Akttyva |
2023-02-23 |
Life Science Valley–Lower Saxony (govt): investment, 202302 fund launch with total of €12m incl €6m from NBank |
2023-02-13 |
Life Science Valley–Sartorius: investment, 202302 fund launch with total of €12m incl €6m from Sartorius + Univ Medical Center Göttingen combined |
2023-02-13 |
Life Science Valley–SEVERAL: investment, 202302 fund launch with €12m incl €6m from Niedersachsen + remainder from Sartorius + Univ Göttingen |
2023-02-13 |
Life Science Valley–Univ Göttingen: investment, 202302 fund launch with total of €12m incl €6m from Univ Medical Center Göttingen + Sartorius combined |
2023-02-13 |
JnJ–Evotec: cancer immunotherapy, 202301– strategic collab + license agreem developm first-in-class targeted immune-based cancer therapies |
2023-01-26 |
Biognosys–Bruker: investment, 202301 acquisition $73.6m of majority share in Biognosys by Bruker |
2023-01-04 |
S-Biomedic–Beiersdorf: investment, 202212 acquisition €na of majority share in S-Biomedic NV by Beiersdorf AG |
2022-12-16 |
Bico–Sartorius: investment, 202212– directed share issue SEK487m (€45m) to existing investor Sartorius resulting 10.1% share + 8.5% of voting rights |
2022-12-08 |
Sartorius–Bico: laboratory equipment, 202212– collab RnD 3D cell printing technologies + digital soluitons for cell line development workflows |
2022-12-08 |
Sartorius–Bico: laboratory equipment, 202212– distribution of Bico products in APAC region by Sartorius |
2022-12-08 |
Cajal Neuroscience–Evotec: investment, 202211 financing round Series A totalling $96m incl existing + co-investor Evotec |
2022-11-29 |
Sartorius–SEVERAL: credit, 202211– placement of total of €650m Schulschein loans with 3, 5, 7, 10 + 13 years maturity |
2022-11-11 |
Centogene–BC Platforms: data integration and analysis s/w, 202211– collab Centogene launches Biodata Network on BCRQUEST.com of BC Platforms |
2022-11-03 |
Evotec–MHH: biospecimen, 202210– collab access to SjS + SLE patient biospecimen for analysis with PanOmics platform to expand E.MPD database |
2022-10-25 |
Evotec–Adapsyn Biotechnology: drug discovery, 202209– strategic collab €na providing Evotec with access to drug-like small molecules for screening |
2022-09-21 |
Indivumed–CellPhenomics: drug target research, 202209– collab to develop platform for cancer drug target discovery + validation |
2022-09-07 |
Central Glass–Evotec: investment, 202208–202211 acquisition of Central Glass Germany GmbH for € 1 by Evotec |
2022-08-25 |
ChemDiv–Schaffhausen Institute of Technology: drug discovery, 202208– collab strategic establishment of dedicated research group at Jacobs Univ |
2022-08-11 |
Trace Analytics–908 Devices: investment, 202208 acquisition $15.3m upfront cash + $2m cash milestones |
2022-08-09 |
Corat Therapeutics–Germany (govt): grant, 202207– up to €38.7m funding from BMBF for pivotal trial of Covid-19 drug candidate COR-101 |
2022-07-13 |
Boehringer–Evotec: investment, 202207 launch of €40m joint venture Aurobac incl €5m from co-investor Evotec |
2022-07-06 |
Life Science Valley–Lower Saxony (govt): grant, 202207–202412 project grant funding €5m with €2m for business incubator + €3m directly for start-ups |
2022-07-01 |
Molzym–OTHER: investment, 202206 investment 2-digit €m from large single family office |
2022-06-29 |
Carma Fund–Evotec: investment, 202206 first closing totalling €47m of Carma Fund I incl investor Evotec SE |
2022-06-21 |
Ymmunobio–Yumab: cancer antibody drug, 202206– collab €na optimisation of CEACAM antibodies by Yumab |
2022-06-16 |
JnJ–Evotec: drug discovery services, 202206– collab discover novel mode of action drugs using TargetAlloMod platforms for Janssen Pharmaceutica |
2022-06-14 |
Rigenerand–Evotec: investment, 202205–202207 acquisition 100% for €23m |
2022-05-30 |
Almirall–Evotec: drug discovery services, 202205– collab multi-target RnD alliance in medical dermatology |
2022-05-19 |
HH2E–Foresight Group: investment, 202205 financing round totalling at least €12m incl Foresight Group acquiring minority share |
2022-05-16 |
HH2E–HydrogenOne Capital: investment, 202205 financing round totalling at least €12m incl HydrogenOne Capital acquiring minority share |
2022-05-16 |
HH2E–SEVERAL: investment, 202205 financing round at least €12m with HydrogenOne Capital + Foresight Group aquiring minoirty stakes ANNOUNCED |
2022-05-16 |
Tubulis–Evotec: investment, 202205 financing round Series B totalling €60m incl new + co-investor Evotec |
2022-05-03 |